Lesson
Open the Fungal Cell Wall
Echinocandins are cyclic lipopeptides that inhibit beta-1,3-D-glucan synthase, weakening a fungal structure absent from mammalian cells.
- Cyclic peptide
- Lipid side chain
- Glucan synthase
- Fks subunit
- Osmotic failure
Keep organism, product, exposure, source, toxicity, and ownership connected.
Keep organism, product, exposure, source, toxicity, and ownership connected.
Keep organism, product, exposure, source, toxicity, and ownership connected.
Keep organism, product, exposure, source, toxicity, and ownership connected.
Locate the pharmacophore
A large cyclic peptide core and lipophilic side chain support membrane association near the glucan synthase complex. This architecture contributes to potent target engagement and absent useful oral bioavailability.
Remove structural glucan
The Fks catalytic complex produces beta-1,3-D-glucan. Inhibition weakens the wall, alters shape and osmotic stability, and is generally fungicidal against susceptible Candida.
Separate wall from membrane
Echinocandins do not bind ergosterol and do not inhibit CYP51. Their mammalian selectivity follows from targeting a fungal wall component that human cells do not produce.
Read Aspergillus differently
The class damages growing hyphal tips but is not routine stand-alone initial treatment for invasive aspergillosis. Selected salvage or combination use requires syndrome-specific evidence.
Quick check
Lesson
Choose the Organism and Compartment
Echinocandins are central to invasive Candida care, but species, site, source, susceptibility, and host determine whether class activity becomes clinical success.
- Candidemia
- Candidozyma auris
- Candida parapsilosis
- Deep sites
- Colonization
Keep organism, product, exposure, source, toxicity, and ownership connected.
Keep organism, product, exposure, source, toxicity, and ownership connected.
Keep organism, product, exposure, source, toxicity, and ownership connected.
Keep organism, product, exposure, source, toxicity, and ownership connected.
Use the class for invasive Candida
Daily echinocandins remain recommended initial therapy for many adults with candidemia, especially with critical illness, prior azole exposure, or concern for azole resistance.
Interpret species carefully
Candida parapsilosis has intrinsically higher echinocandin MICs than many Candida species. Candida glabrata can acquire FKS resistance. Species identification and susceptibility guide refinement.
Treat Candida auris as two systems
Clinical infection generally receives initial echinocandin therapy with susceptibility and response monitoring. Colonization is not treated, but infection-control precautions and public-health coordination remain essential.
Respect limited compartments
Urine, eye, CNS, prostate, valve, bone, abscess, and infected hardware create exposure or source-control problems. Bloodstream activity cannot be generalized to every deep site.
Quick check
Lesson
Build the Caspofungin Regimen
Caspofungin uses indication-specific loading and maintenance, a unique hepatic and inducer pathway, and a saline-based preparation system.
- 70 mg load
- 50 mg daily
- 35 mg hepatic dose
- Inducers
- No dextrose
Keep organism, product, exposure, source, toxicity, and ownership connected.
Keep organism, product, exposure, source, toxicity, and ownership connected.
Keep organism, product, exposure, source, toxicity, and ownership connected.
Keep organism, product, exposure, source, toxicity, and ownership connected.
Protect the adult loading dose
Most adult invasive indications use 70 mg once on day one followed by 50 mg daily. Esophageal candidiasis uses 50 mg daily without the studied loading regimen.
Adjust moderate hepatic impairment
Current labeling recommends 35 mg daily for adults with Child-Pugh 7 to 9 after a 70 mg load when appropriate. Severe hepatic impairment lacks a validated label pathway.
Respond to specified inducers
Rifampin uses 70 mg daily. A 70 mg daily dose should be considered with efavirenz, nevirapine, carbamazepine, dexamethasone, or phenytoin according to current labeling.
Keep dextrose out of the pathway
Caspofungin should not be mixed or diluted with dextrose-containing solutions. Use the exact labeled reconstitution, saline dilution, approximately one-hour infusion, and line-separation process.
Quick check
Lesson
Match Micafungin Dose to Its Role
Micafungin has distinct adult doses for invasive candidiasis, esophageal disease, and HSCT prophylaxis, with age-specific pediatric exposure and product-specific monitoring.
- 100 mg
- 150 mg
- 50 mg prophylaxis
- Pediatrics
- Organ and interaction safety
Keep organism, product, exposure, source, toxicity, and ownership connected.
Keep organism, product, exposure, source, toxicity, and ownership connected.
Keep organism, product, exposure, source, toxicity, and ownership connected.
Keep organism, product, exposure, source, toxicity, and ownership connected.
Separate adult roles
Adult invasive candidiasis uses 100 mg daily, esophageal candidiasis uses 150 mg daily, and Candida prophylaxis in HSCT recipients uses 50 mg daily under current labeling.
Use age-specific pediatric logic
Children at least four months old use weight-based dosing with indication-specific maximums. Patients younger than four months use a distinct 4 mg/kg invasive-disease regimen when CNS or ocular dissemination is absent.
Do not overclaim neonatal CNS dosing
The effectiveness of a micafungin dose for Candida meningoencephalitis in young infants is not established. Higher exposure has limited data and requires specialist-guided interpretation.
Monitor the actual product
Hypersensitivity, hepatic, renal, hematologic, infusion, and injection-site effects remain visible. Micafungin can also increase sirolimus, itraconazole, or nifedipine exposure.
Quick check
Lesson
Use Anidulafungin's Distinct Elimination
Anidulafungin couples loading-dose exposure with slow chemical degradation, limited CYP involvement, no labeled organ adjustment, and a strict infusion-rate ceiling.
- 200 mg load
- 100 mg daily
- Ring opening
- No organ adjustment
- 1.1 mg per minute
Keep organism, product, exposure, source, toxicity, and ownership connected.
Keep organism, product, exposure, source, toxicity, and ownership connected.
Keep organism, product, exposure, source, toxicity, and ownership connected.
Keep organism, product, exposure, source, toxicity, and ownership connected.
Load invasive candidiasis
Adults receive 200 mg once followed by 100 mg daily for candidemia and other invasive Candida infections. Esophageal candidiasis uses 100 mg once followed by 50 mg daily.
Follow nonenzymatic degradation
At physiologic conditions, the ring slowly opens into an inactive peptide that is further degraded. Human CYP enzymes do not drive its principal elimination pathway.
Avoid unsupported organ reductions
Current labeling requires no renal or hepatic dose adjustment, including dialysis. This pharmacokinetic rule does not remove liver, kidney, symptom, or infusion surveillance.
Calculate infusion time
The rate must not exceed 1.1 mg per minute. Labeled preparation yields about 45 minutes for 50 mg, 90 minutes for 100 mg, and 180 minutes for a 200 mg load.
Quick check
Lesson
Build a Safe Weekly Rezafungin Calendar
Rezafungin combines a very long half-life with restricted current eligibility, once-weekly infusion, missed-dose logic, photosensitivity, and a limited studied duration.
- Age 12 or older
- Limited alternatives
- 400 mg load
- 200 mg weekly
- Four-dose boundary
Keep organism, product, exposure, source, toxicity, and ownership connected.
Keep organism, product, exposure, source, toxicity, and ownership connected.
Keep organism, product, exposure, source, toxicity, and ownership connected.
Keep organism, product, exposure, source, toxicity, and ownership connected.
Apply the current indication
Current 2026 labeling includes adults and patients age 12 years or older who have limited or no alternatives for candidemia and invasive candidiasis. It has not been studied for Candida endocarditis, osteomyelitis, or meningitis.
Protect the weekly regimen
Give 400 mg intravenously as the initial load, then 200 mg once weekly. Safety has not been established beyond four weekly doses, including the loading dose.
Recalculate after a delay
A dose given within three days of the assigned day preserves the next scheduled date. A delay beyond three days requires at least four days before the next dose. A gap of at least two weeks requires reloading.
Use product-specific surveillance
Hypersensitivity, infusion reactions, photosensitivity, liver abnormalities, neurologic symptoms, and gastrointestinal or electrolyte effects belong in the plan. Counsel on UV protection during treatment.
Quick check
Lesson
Treat Preparation as Product Specific
The class is intravenous, but reconstitution, dilution, concentration, compatible carrier, co-infusion, storage, and rate differ by product.
- Product identity
- Diluent
- Concentration
- Line
- Infusion reaction
Keep organism, product, exposure, source, toxicity, and ownership connected.
Keep organism, product, exposure, source, toxicity, and ownership connected.
Keep organism, product, exposure, source, toxicity, and ownership connected.
Keep organism, product, exposure, source, toxicity, and ownership connected.
Do not borrow another recipe
Caspofungin excludes dextrose, while micafungin and anidulafungin have different compatible diluents and concentrations. Rezafungin has its own reconstitution and 250 mL infusion pathway.
Verify the complete preparation
Confirm product, dose, vial count, reconstitution volume, withdrawal volume, bag, final concentration, storage limit, line, co-infusion, pump, and duration before administration.
Classify histamine symptoms
Flushing, rash, pruritus, swelling, warmth, bronchospasm, hypotension, nausea, or chest tightness can occur. Slow or pause appropriate reactions, but do not normalize severe airway or circulatory findings.
Treat anaphylaxis immediately
Discontinue exposure and begin emergency evaluation and treatment for suspected anaphylaxis. A prior mild infusion reaction does not make later hypotension or wheeze routine.
Quick check
Lesson
Find Failure at the Fks Target
FKS hotspot substitutions can reduce echinocandin susceptibility, especially after exposure, while Candida auris adds transmission and public-health consequences.
- FKS1
- FKS2
- MIC
- Prior exposure
- Candida auris
Keep organism, product, exposure, source, toxicity, and ownership connected.
Keep organism, product, exposure, source, toxicity, and ownership connected.
Keep organism, product, exposure, source, toxicity, and ownership connected.
Keep organism, product, exposure, source, toxicity, and ownership connected.
Locate target resistance
FKS hotspot substitutions change the glucan synthase target and can predict clinical failure. Candida glabrata commonly involves FKS1 or FKS2, while Candida auris resistance often involves FKS1.
Interpret susceptibility in context
Species, method, current breakpoint, MIC, prior echinocandin, dosing, and clinical response all matter. Candida parapsilosis has higher baseline MICs that should not be mislabeled without context.
Audit persistent cultures
Reopen source control, catheter, abscess, site exposure, product, dose, preparation, host immunity, organism identification, susceptibility, and FKS testing before blind escalation.
Keep infection control active
Candida auris can remain colonizing and transmissible after clinical cure. Accurate identification, facility precautions, state or local reporting, and susceptibility surveillance continue beyond antifungal therapy.
Quick check
Lesson
Make Clearance and Source Control Visible
Candidemia success depends on repeat cultures, source control, metastatic-site evaluation, adequate duration, and a verified oral transition.
- Repeat cultures
- Source
- Duration clock
- Deep sites
- Step-down
Keep organism, product, exposure, source, toxicity, and ownership connected.
Keep organism, product, exposure, source, toxicity, and ownership connected.
Keep organism, product, exposure, source, toxicity, and ownership connected.
Keep organism, product, exposure, source, toxicity, and ownership connected.
Document bloodstream clearance
Repeat blood cultures daily or every other day establish the clearance date. Uncomplicated candidemia is generally treated for two weeks after clearance and symptom resolution.
Control the anatomic source
Remove or manage infected catheters and devices when appropriate, drain collections, debride necrotic tissue, and relieve obstruction. Persistent exposure cannot compensate for an uncontrolled focus.
Search when the course is not uncomplicated
Persistent cultures, focal symptoms, visual findings, murmur, hardware, neurologic change, bone pain, abdominal source, or urinary obstruction can require deeper evaluation and longer therapy.
Verify oral step-down
Clinical stability, susceptible isolate, negative repeat cultures, source control, reliable oral absorption, manageable interactions, adherence, and follow-up support transition from intravenous therapy.
Quick check
Lesson
Close the Echinocandin Loop
Safe use connects diagnosis, exact product, dose, preparation, infusion, cultures, susceptibility, source, toxicity, transition, and accountable follow-up.
- Baseline
- Monitoring
- Failure audit
- Reproductive context
- Ownership
Keep organism, product, exposure, source, toxicity, and ownership connected.
Keep organism, product, exposure, source, toxicity, and ownership connected.
Keep organism, product, exposure, source, toxicity, and ownership connected.
Keep organism, product, exposure, source, toxicity, and ownership connected.
Verify the baseline
Confirm syndrome, host, organism evidence, site, source, product, indication, age, weight or body surface area, liver and kidney status, interactions, reproductive context, preparation, and monitoring owner.
Monitor dynamically
Follow cultures, source, symptoms, infusion physiology, liver tests, kidney function, blood counts when relevant, susceptibility, and product-specific adverse effects. A favorable class reputation is not a monitoring plan.
Audit failure broadly
Recheck diagnosis, species, source, site, dose, loading, preparation, compatibility, host, susceptibility, FKS resistance, and tissue exposure before calling the entire class ineffective.
Own the transition
Document clearance, duration endpoint, source status, oral transition criteria, pending tests, symptom escalation, infection-control needs, follow-up timing, and the clinician responsible for every result.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 176 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.